FDA Gives ‘Dragons Blood’ To Big Pharma
The FDA has taken a freely-available herbal product, sap of the dragon’s blood tree, defined it as the drug Fulyzac, & handed it to Big Pharma. Nature’s gift is being polluted. What you get after Big Pharma and & the FDA get their hands on it has lost much of its value and often been rendered into a poison, the very nature of a drug.
An extract from a South American tree known as dragon’s blood is now classed as a drug and the FDA has handed sole rights to a single pharmaceutical corporation. The drug, which is made by Salix Pharmaceuticals, will be sold by Napo Pharmaceuticals of San Francisco under the brand name of Fulyzac. The generic term for it is crofelemer. It will be sold as a treatment for the diarrhea that’s a common adverse effect of harsh HIV drugs.
The tree is botanically named¬†Croton lechleri¬†and called sangre de grado in Spanish and Portuguese,¬†Long known to have several health benefits, extract from the tree¬†is commonly available in health food stores around the world. This, though, is likely to change in the face of the FDA’s action. It signals their role in facilitating Big Pharma’s takeover of the natural world’s largesse. Piece by piece, anything that holds any health value is being declared a drug. Exclusive rights to that drug are then handed over to a private corporation.
That’s what happened to pregnenolone, a natural hormone that was routinely and inexpensively produced by compounding pharmacies, which provided it to pregnant women to prevent miscarriages.The FDA first targeted the compounding pharmacies, ordering them to stop producing it. Then, they handed exclusive rights to pregnenolone to a single corporation, which then turned around and raised the price 15,000 percent! That increase has taken it out of the reach of most women, making it available only to those of wealth or good insurance.